MX2020003546A - Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento. - Google Patents

Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.

Info

Publication number
MX2020003546A
MX2020003546A MX2020003546A MX2020003546A MX2020003546A MX 2020003546 A MX2020003546 A MX 2020003546A MX 2020003546 A MX2020003546 A MX 2020003546A MX 2020003546 A MX2020003546 A MX 2020003546A MX 2020003546 A MX2020003546 A MX 2020003546A
Authority
MX
Mexico
Prior art keywords
treatment
methods
pharmaceutical formulation
extended release
release pharmaceutical
Prior art date
Application number
MX2020003546A
Other languages
English (en)
Inventor
Paul William Glue
Natalie June Medlicott
Peter William Surman
Original Assignee
Douglas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/728,695 external-priority patent/US10441544B2/en
Application filed by Douglas Pharmaceuticals Ltd filed Critical Douglas Pharmaceuticals Ltd
Publication of MX2020003546A publication Critical patent/MX2020003546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona una formulación oral de liberación prolongada para el tratamiento de la depresión resistente al tratamiento, la ansiedad resistente al tratamiento y la fobia.
MX2020003546A 2017-10-10 2018-10-10 Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento. MX2020003546A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/728,695 US10441544B2 (en) 2017-10-10 2017-10-10 Extended release pharmaceutical formulation
US201862695966P 2018-07-10 2018-07-10
PCT/IB2018/057851 WO2019073408A1 (en) 2017-10-10 2018-10-10 PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS

Publications (1)

Publication Number Publication Date
MX2020003546A true MX2020003546A (es) 2020-08-03

Family

ID=66101315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003546A MX2020003546A (es) 2017-10-10 2018-10-10 Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.

Country Status (8)

Country Link
US (2) US12350379B2 (es)
EP (1) EP3694832A4 (es)
JP (1) JP7364558B2 (es)
CN (1) CN111630026A (es)
AU (1) AU2018348359C1 (es)
CA (1) CA3077645A1 (es)
MX (1) MX2020003546A (es)
WO (1) WO2019073408A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
MX2020003546A (es) 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
KR20220002905A (ko) * 2019-03-25 2022-01-07 더글라스 파머수티클스 리미티드 서방형 약학 제제
IL294089B1 (en) 2019-12-20 2026-07-01 Alar Pharmaceuticals Inc Injectable, long-acting formulations of ketamine pamoate salts
JP2023507926A (ja) * 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
WO2021137147A1 (en) * 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023543211A (ja) * 2020-09-24 2023-10-13 ダグラス ファーマシューティカルズ エルティーディー． 徐放性医薬製剤
US20240207338A1 (en) * 2021-04-30 2024-06-27 Progressive Therapeutics Inc Ketamine and cannabis for the treatment of emotional disorders
JP7847101B2 (ja) * 2023-06-26 2026-04-16 クラレトレーディング株式会社 動物忌避樹脂組成物、動物忌避樹脂成形体、及び動物忌避樹脂成形体物品

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
JP4815053B2 (ja) 1998-08-13 2011-11-16 シーマ・ラブス、インコーポレイテッド 経口投与の固形投与形態物としてのマイクロエマルション
US6692771B2 (en) 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US6855735B2 (en) 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
CA2522471A1 (en) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
WO2006024018A2 (en) 2004-08-24 2006-03-02 Neuromolecular Pharmaceuticals, Inc. Compositions for treating nociceptive pain
WO2006042249A2 (en) 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain
EP1969117A4 (en) 2005-12-13 2008-12-17 Trinity Lab Inc A method to treat premature ejaculation in humans
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CN101441401B (zh) 2007-11-20 2012-07-04 深圳迈瑞生物医疗电子股份有限公司 快速确定超声成像系统中成像区域的方法和装置
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
WO2009131794A1 (en) 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
ES2607209T3 (es) * 2009-02-06 2017-03-29 Egalet Ltd. Composiciones farmacéuticas resistentes al abuso
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2588820B1 (en) 2010-06-30 2019-08-07 LG Electronics Inc. Refrigerator
WO2012056246A1 (en) 2010-10-28 2012-05-03 Shire Llc Combination treatment of major depressive disorder
PH12013501345A1 (en) * 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
CO6330164A1 (es) 2011-07-12 2011-10-20 Univ Del Valle Método para producir fibras de celulosa y de hemicelulosa de alta resistencia a partir de biomasa lignocelulósica de las hojas y cogollos de la caña de azúcar
JP6296985B2 (ja) 2011-10-14 2018-03-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
JP2015512418A (ja) 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US20140020155A1 (en) 2012-07-19 2014-01-23 David Israel Elastic stretching gathered denim fabric jean
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
KR20220044380A (ko) 2013-04-12 2022-04-07 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
US20160106808A1 (en) * 2013-05-13 2016-04-21 Icahn School Of Medicine At Mount Sinai Treatment of Mood and Anxiety Disorders
US9913803B2 (en) * 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
EP3272338B1 (en) 2014-04-17 2020-09-09 Develco Pharma Schweiz AG Oral dosage form of ketamine
US11207316B2 (en) 2014-05-30 2021-12-28 West Virginia University Ketamine or dextromethorphan formulations and methods of use
US10114883B1 (en) 2014-09-30 2018-10-30 Apple Inc. Generating preferred metadata for content items
KR102604397B1 (ko) * 2014-11-04 2023-11-21 아카디아 파마슈티칼스 인코포레이티드 신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법
EP3641742B1 (en) 2017-06-23 2026-03-25 Ketabon GmbH Hydroxynorketamine for the use in the treatment of depression
US12090123B2 (en) * 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
MX2020003546A (es) 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation

Also Published As

Publication number Publication date
US12350379B2 (en) 2025-07-08
EP3694832A1 (en) 2020-08-19
JP7364558B2 (ja) 2023-10-18
US12350378B2 (en) 2025-07-08
US20220347104A1 (en) 2022-11-03
WO2019073408A1 (en) 2019-04-18
JP2020536901A (ja) 2020-12-17
AU2018348359C1 (en) 2023-10-12
CN111630026A (zh) 2020-09-04
AU2018348359A8 (en) 2020-04-30
AU2018348359B2 (en) 2023-07-13
US20220354798A1 (en) 2022-11-10
AU2018348359A1 (en) 2020-04-23
EP3694832A4 (en) 2021-07-14
CA3077645A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
AU2018348359A8 (en) Extended release pharmaceutical formulation and methods of treatment
ECSP19078196A (es) Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
BR112019007806A2 (pt) composição bucal de múltiplas fases para a liberação de agentes ativos para tratamento bucal
CL2018002359A1 (es) Métodos para usar agonistas de fxr
CY1123295T1 (el) Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης
CL2017000824A1 (es) Moduladores de regulador de conducta de transmembranas de fibrosis cística
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
CL2016002495A1 (es) Derivados de piridina macrocíclicos .
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CY1119489T1 (el) Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
EP3604353A4 (en) PHOTOCURING COMPOSITION, BASE FOR DENTAL PROSTHESIS, AND DENTIST
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
EP3618819A4 (en) TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
MX2019007178A (es) Composiciones para el cuidado bucal.
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
CL2019001038A1 (es) Composición para el cuidado bucal.
MX2021010207A (es) Formulacion farmaceutica de liberacion extendida.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.